{"id":204048,"date":"2010-01-20T11:41:17","date_gmt":"2010-01-20T16:41:17","guid":{"rendered":"http:\/\/www.technologytransfertactics.com\/content\/?p=5739"},"modified":"2010-01-20T11:41:17","modified_gmt":"2010-01-20T16:41:17","slug":"roswell-park-licenses-tumor-imaging-tech-to-chinese-pharma","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/204048","title":{"rendered":"Roswell Park licenses tumor imaging tech to Chinese pharma"},"content":{"rendered":"<p>Roswell Park Cancer Institute&#8217;s (RPCI) TTO has signed a licensing agreement with Zhejiang Hisun Pharmaceutical Co., Ltd., for tumor imaging technology developed by RPCI researcher Ravindra Pandey, PhD. Zhejiang Hisun Pharmaceutical is one of China&#8217;s largest producers of oncology drugs. Additional terms were not disclosed, but Richard Matner, PhD, MBA, director of RPCI&#8217;s TTO, recently spoke about the institute&#8217;s focus on deal-making in Asia in an interview with <em>Technology Transfer Tactics<\/em>. &#8220;We&#8217;ve found that, overall, the capacity for risk tolerance is higher in Asia than in the U.S. or Europe,&#8221; Matner said. &#8220;Assets or free capital move projects forward, and there&#8217;s a higher level in China and India. Right now China&#8217;s got $2 trillion in the bank and a straightforward mission from the Premier to bring various therapies into China. We&#8217;ve been a little ahead of the curve in that we&#8217;ve been negotiating in Asia for some time.&#8221;<\/p>\n<p>The RPCI tumor imaging technology also shows potential as an anti-cancer treatment agent, according to Hua Bai, president and CEO of Zhejiang Hisun. &#8220;We believe a drug with these properties would be extremely valuable for patients in China,&#8221; he says. &#8220;It may play a significant role in improving treatment options for people with cancer and will greatly enrich Zhejiang Hisun&#8217;s growing oncology drug pipeline.&#8221;<\/p>\n<p>Source: <a href=\"http:\/\/www.newswise.com\/articles\/roswell-park-cancer-institute-licenses-tumor-imaging-technology-to-chinese-pharmaceutical-company\" >Newswise<\/a><\/p>\n<p><br class=\"spacer_\" \/><\/p>\n<p><br class=\"spacer_\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Roswell Park Cancer Institute&#8217;s (RPCI) TTO has signed a licensing agreement with Zhejiang Hisun Pharmaceutical Co., Ltd., for tumor imaging technology developed by RPCI researcher Ravindra Pandey, PhD. Zhejiang Hisun Pharmaceutical is one of China&#8217;s largest producers of oncology drugs. Additional terms were not disclosed, but Richard Matner, PhD, MBA, director of RPCI&#8217;s TTO, recently [&hellip;]<\/p>\n","protected":false},"author":67,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-204048","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/204048","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/67"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=204048"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/204048\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=204048"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=204048"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=204048"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}